Search clinical trials for: HER2-neg

Total 326 results

European Organisation for Research and Treatment...

Not yet recruiting

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Women With Early Breast Cancer; A Pragmatic Randomized Controlled Trial

Musculoskeletal Pain | Drug-Related Side Effects and Adverse Reactions | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | HER2-negative Breast Cancer | ER+ Breast Cancer
Mayo Clinic

Recruiting

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients

Metastatic Breast Cancer | HER2-negative Breast Cancer | Hormone-receptor-positive Breast Cancer

United States
MedSIR
Stemline Therapeutics, Inc.

Not yet recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (ADELA)

Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | ESR1 Gene Mutation
Hebei Medical University Fourth Hospital

Recruiting

Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer

Breast Cancer | HER2-negative Breast Cancer

China
Medical College of Wisconsin

Not yet recruiting

Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

Breast Cancer

United States
Filipa Lynce, MD
Merck Sharp & Dohme LLC; Zentalis Pharmaceuticals

Not yet recruiting

A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT)

Breast Cancer | Triple Negative Breast Cancer | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor Negative Malignant Tumor Breast Triple

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Not yet recruiting

New Digital Person-based Care Model in Patients With HER2-negative Advanced Breast Cancer (InPERSON)

Breast Cancer | Patient Satisfaction | Narrative Medicine | HER2-negative Breast Cancer
Fudan University

Recruiting

Abemaciclib, Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Breast Cancer

China
Fudan University

Recruiting

Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Breast Cancer

China
Nuvation Bio Inc.

Recruiting

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Pancreatic Cancer | Advanced Solid Tumor | HER2-negative Breast Cancer | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Platinum-resistant Ovarian Cancer (PROC)

United States
Zhejiang Cancer Hospital

Not yet recruiting

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Metastatic Breast Cancer

China
Lin Chen

Recruiting

Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer

Efficacy | Safety | HER2 Negative | Locally Advanced Gastric Carcinoma

China
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Hormone Receptor Positive Malignant Neoplasm of Breast | HER2-negative Breast Cancer | Hormone-receptor-positive Breast Cancer

China
Fudan University

Recruiting

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

HER2-negative Breast Cancer | Leptomeningeal Metastasis

China
Sarah Sammons, MD
Daiichi Sankyo

Recruiting

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Breast Cancer | Breast Cancer Female | Metastatic Triple-Negative Breast Carcinoma | HER2-negative Breast Cancer | HER2 Negative Breast Carcinoma | ER-negative Breast Cancer | ER Positive Breast Cancer

United States
AstraZeneca

Not yet recruiting

NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients (iRetroBC)

HER2-negative
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Breast Neoplasms

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Breast Neoplasms

China
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Advanced Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive...

Australia, United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Mobile Health for Adherence in Breast Cancer Patients

Breast Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
Medical College of Wisconsin

Not yet recruiting

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

Breast Cancer

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Advanced or Metastatic Breast Cancer

United States, Israel, Taiwan, Argentina, Japan, Korea, Republic of, Canada, Australia, Brazil
Guangdong Provincial People's Hospital
Sun Yat-sen University; First Affiliated Hospital, Sun Yat-Sen University; Shantou...

Recruiting

Organoid-based Functional Precision Therapy for Advanced Breast Cancer (ORIENTA)

Advanced Breast Cancer | HER2-negative Breast Cancer

China
National Cancer Institute (NCI)

Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma

United States
Margaret Gatti-Mays

Recruiting

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma

United States
Olema Pharmaceuticals, Inc.

Recruiting

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2 Negative Breast Carcinoma | ER Positive Breast Cancer

United States, Korea, Republic of, Australia, Hong Kong, Taiwan, Malaysia, Thailand, Argentina, Belgium, Portugal
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Patients With Low Risk, Hormone Responsive Breast Cancer

Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma | Estrogen Receptor-Positive Breast Carcinoma

United States
Yale University
AstraZeneca

Not yet recruiting

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

Breast Cancer | Hyperinsulinism | HER2-negative Breast Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Breast Neoplasms

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Breast Neoplasms

China
SOLTI Breast Cancer Research Group

Recruiting

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (SOLTI-2104)

Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Premenopausal Breast Cancer

Spain
Memorial Sloan Kettering Cancer Center
AstraZeneca; Novartis Pharmaceuticals

Recruiting

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Breast Cancer

United States
Carrick Therapeutics Limited
Berlin-Chemie AG Menarini Group

Recruiting

A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer (SUMIT-ELA)

Breast Cancer | Metastatic Breast Cancer | Locally Advanced Breast Cancer

United States, France, Spain, United Kingdom
Carrick Therapeutics Limited
Pfizer

Recruiting

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (SUMIT-BC)

Breast Cancer | Metastatic Breast Cancer | Locally Advanced Breast Cancer

Spain, United States, Turkey, Hungary
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer (VERITAC-3)

Breast Cancer

United States, China, Spain, Hungary, Japan, Australia, Brazil, Italy, Slovakia, Switzerland
Artios Pharma Ltd

Recruiting

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Advanced Solid Tumor | Metastatic Solid Tumor

United States
Semmelweis University

Recruiting

Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer (NeoHTerMa)

HER2-negative Breast Cancer

Hungary
Institut fuer Frauengesundheit
Novartis Pharmaceuticals; AGO Breast Study Group e.V.

Recruiting

CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer (CLEAR-B)

Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer

Germany
QuantumLeap Healthcare Collaborative

Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program (PRE-I-SPY-PI)

Solid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditions

United States
University of Miami

Recruiting

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Breast Cancer | Metastatic Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer

United States
Scorpion Therapeutics, Inc.

Recruiting

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Breast Cancer | Gynecologic Cancer | HNSCC | Solid Tumors, Adult

United States, Spain
Totus Medicines

Recruiting

A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors

Cervical Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of Head and Neck | Endometrial Cancer | Non-small Cell Lung Cancer | Urothelial Carcinoma | HER2-negative Breast Cancer

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Triple-Negative Breast Carcinoma | HER2-Negative Breast Carcinoma | Hormone Receptor-Negative Breast Carcinoma

United States
Centre Antoine Lacassagne

Recruiting

Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS) (CALHYS)

HER2 Negative Breast Cancer Not Immediately Operated

France
The Methodist Hospital Research Institute
Novartis Pharmaceuticals

Recruiting

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Metastatic Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Metaplastic Breast Carcinoma

United States
Accutar Biotechnology Inc

Recruiting

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2)

Advanced Breast Cancer

China, Japan, United States, Taiwan, Canada, Korea, Republic of, Spain, Bulgaria, Turkey, Finland, Italy, Czechia, India, Slovakia, South Africa, Germany, Australia, Brazil, Greece, Puerto Rico, Belgium, Argentina, Switzerland, Poland, ... and more
Novartis Pharmaceuticals

Recruiting

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment (ALPINIST)

Advanced Breast Cancer

India
Atossa Therapeutics, Inc.
InClin

Recruiting

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (EVANGELINE)

Breast Neoplasms | Invasive Breast Cancer | HER2-negative Breast Cancer | Estrogen-receptor-positive Breast Cancer

United States

Search clinical trials for: HER2-neg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations